Literature DB >> 33990158

Cross-sectional study of plasma Axl, ferritin, IGFBP4 and sTNFR2 as biomarkers of disease activity in childhood-onset SLE: A study of the Pediatric Nephrology Research Consortium.

Samar A Soliman1,2, Anam Haque1, Sherene Mason3, Larry A Greenbaum4, M John Hicks5, Chandra Mohan1, Scott E Wenderfer5.   

Abstract

OBJECTIVE: To evaluate the performance of 4 plasma protein markers for detecting disease activity in childhood-onset systemic lupus erythematosus (SLE) patients.
METHODS: Eighty-three consecutive pediatric patients fulfilling ≥4 ACR criteria for SLE and twenty-five healthy controls were prospectively recruited for serological testing of 4 protein markers identified by antibody-coated microarray screen, namely Axl, ferritin, IGFBP4 and sTNFR2. SLE disease activity was assessed using SLEDAI-2000 score. Fifty-seven patients had clinically active SLE (SLEDAI score ≥4, or having a flare).
RESULTS: The plasma concentrations of Axl and ferritin were significantly higher in patients with active SLE than inactive SLE. Plasma Axl levels were significantly higher in active renal versus active non-renal SLE patients. Levels of Axl, ferritin and IGFBP4 correlated significantly with SLEDAI scores. Levels of Axl, IFGBP4 and sTNFR2 inversely correlated with plasma complement C3 levels. Only plasma Axl and ferritin levels correlated with degree of proteinuria. These markers were more specific, but less sensitive, in detecting concurrent SLE activity than elevated anti-dsDNA antibody titer or decreased C3. Ferritin and IGFBP4 levels were more specific for concurrent active lupus nephritis than anti-dsDNA or C3. Plasma ferritin was the best monitor of global SLE activity, followed by C3 then Axl, while both Axl and C3 were best monitors of clinical lupus nephritis activity.
CONCLUSION: In childhood-onset SLE patients, plasma ferritin and Axl perform better than traditional yardsticks in identifying disease activity, either global or renal. The performance of these plasma markers should be explored further in longitudinal cohorts of SLE patients.

Entities:  

Keywords:  Lupus nephritis; biomarkers; kidney diseases; lupus erythematosus; pediatrics; proteomics; systemic

Mesh:

Substances:

Year:  2021        PMID: 33990158      PMCID: PMC8282643          DOI: 10.1177/09612033211016100

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  45 in total

1.  Monocyte and plasma expression of TAM ligand and receptor in renal failure: Links to unregulated immunity and chronic inflammation.

Authors:  Iris J Lee; Brendan A Hilliard; Mehriban Ulas; Daohai Yu; Chandan Vangala; Swati Rao; Jean Lee; Crystal A Gadegbeku; Philip L Cohen
Journal:  Clin Immunol       Date:  2015-03-24       Impact factor: 3.969

2.  Association of Serum Ferritin Levels with Hematological Manifestations in Systemic Lupus Erythematosus Patients from Western India.

Authors:  Vandana Pradhan; Pallavi Pandit; Anjali Rajadhyaksha; Manisha Patwardhan; Prathamesh Surve; Pradnya Kamble; Maxime Lecerf; Jagadeesh Bayry; Srinivas Kaveri; K Ghosh; Milind Y Nadkar
Journal:  J Assoc Physicians India       Date:  2016-05

3.  Growth hormone-binding proteins, IGF-I and IGF-binding proteins in children and adolescents with type 1 diabetes mellitus.

Authors:  G Radetti; C Paganini; F Antoniazzi; B Pasquino; R Valentini; L Gentili; L Tato
Journal:  Horm Res       Date:  1997

4.  IGF and IGF-binding protein system in the synovial fluid of osteoarthritic and rheumatoid arthritic patients.

Authors:  C Tavera; T Abribat; P Reboul; S Doré; P Brazeau; J P Pelletier; J Martel-Pelletier
Journal:  Osteoarthritis Cartilage       Date:  1996-12       Impact factor: 6.576

5.  Elevated serum levels of soluble Axl in acute coronary syndrome.

Authors:  Yu-Wei Liu; Qun-Fang Yang; Pei-Yuan Zuo; Chang-Liang Xiao; Xing-Lin Chen; Cheng-Yun Liu
Journal:  Am J Med Sci       Date:  2015-02       Impact factor: 2.378

6.  Systemic lupus erythematosus disease activity index 2000.

Authors:  Dafna D Gladman; Dominique Ibañez; Murray B Urowitz
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

Review 7.  Emerging biological therapies for systemic lupus erythematosus.

Authors:  Chi Chiu Mok
Journal:  Expert Opin Emerg Drugs       Date:  2014-03-03       Impact factor: 4.191

8.  Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with systemic lupus erythematosus and Behçets disease.

Authors:  Tamer A Gheita; Iman H Bassyouni; Rasha H Bassyouni
Journal:  J Clin Immunol       Date:  2012-07-26       Impact factor: 8.317

9.  Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis.

Authors:  Tianfu Wu; Chun Xie; Jie Han; Yujin Ye; Sandeep Singh; Jinchun Zhou; Yajuan Li; Huihua Ding; Quan-zhen Li; Xin Zhou; Chaim Putterman; Ramesh Saxena; Chandra Mohan
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

10.  The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis.

Authors:  Katharina Staufer; Mirko Dengler; Heidemarie Huber; Rodrig Marculescu; Rudolf Stauber; Carolin Lackner; Hans-Peter Dienes; Danijel Kivaranovic; Christian Schachner; Markus Zeitlinger; Beatrix Wulkersdorfer; Peter Rauch; Gerhard Prager; Michael Trauner; Wolfgang Mikulits
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

View more
  2 in total

1.  Urine ALCAM, PF4 and VCAM-1 Surpass Conventional Metrics in Identifying Nephritis Disease Activity in Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Samar A Soliman; Anam Haque; Kamala Vanarsa; Ting Zhang; Faten Ismail; Kyung Hyun Lee; Claudia Pedroza; Larry A Greenbaum; Sherene Mason; M John Hicks; Scott E Wenderfer; Chandra Mohan
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

2.  Clinical significance of serum ferritin in patients with systemic sclerosis.

Authors:  Yanting Jiang; Xi Li; Wei Zhou; Min Jin; Sihui Li; Yuehong Lao; Haiqing Zhu; Jian Wang
Journal:  J Clin Lab Anal       Date:  2022-07-09       Impact factor: 3.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.